Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease
Status:
Not yet recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled study of Trans Sodium Crocetinate (TSC) in patients
with Interstitial Lung Disease (ILD), age 30-85 (inclusive). The primary objective of the
study is to determine the effect of TSC on lung function as measured by diffusing capacity of
the lungs for carbon monoxide (DLCO) in patients with ILD; the secondary objectives are to
determine the effect of TSC on the 6-minute walk test (6MWT), heart rate recovery (HRR), and
Borg Scale in patients with ILD.